Cystatin C-based glomerular filtration rate associates more closely with mortality than creatinine-based or combined glomerular filtration rate equations in unselected patients
- 10 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 23 (15) , 1649-1657
Abstract
Decreased glomerular filtration rate (GFR) is an important cardiovascular risk factor, but estimated GFR (eGFR) may differ depending on whether it is based on creatinine or cystatin C. A combined creatinine/cystatin C equation has recently been shown to best estimate GFR; however, the benefits of using the combined equation for risk prediction in routine clinical care have been less studied. This study compares mortality risk prediction by eGFR using the combined creatinine/cystatin C equation (CKD-EPI), a sole creatinine equation (CKD-EPI) and a sole cystatin C equation (CAPA), respectively, using assays that are traceable to international calibrators. All patients analysed for both creatinine and cystatin C from the same blood sample tube (n = 13,054) during 2005–2007 in Uppsala University Hospital Laboratory were divided into eGFR risk categories>60, 30–60 and 2 by each eGFR equation. During follow-up (median 4.6 years), 4398 participants died, of which 1396 deaths were due to cardiovascular causes. Reduced eGFR was significantly associated with death as assessed by all eGFR equations. The net reclassification improvement (NRI) for the combination equation compared with the sole creatinine equation was 0.10 (p < 0.001) for all-cause mortality and 0.08 (p < 0.001) for cardiovascular mortality, indicating improved reclassification. In contrast, NRI for the combination equation, compared with the sole cystatin C equation, was –0.06 (p < 0.001) for all-cause mortality and –0.02 (p = 0.032) for cardiovascular mortality, indicating a worsened reclassification. In routine clinical care, cystatin C-based eGFR was more closely associated with mortality compared with both creatinine-based eGFR and creatinine/cystatin C-based eGFR.Keywords
This publication has 32 references indexed in Scilit:
- Cystatin C– and Creatinine-Based Estimates of Renal Function and Their Value for Risk Prediction in Patients with Acute Coronary Syndrome: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) StudyClinical Chemistry, 2013
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice GuidelineAnnals of Internal Medicine, 2013
- Standards of Medical Care in Diabetes—2013Diabetes Care, 2012
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Estimated GFR Associates with Cardiovascular Risk Factors Independently of Measured GFRJournal of the American Society of Nephrology, 2011
- Significant differences when using creatinine, modification of diet in renal disease, or cystatin C for estimating glomerular filtration rate in ICU patientsUpsala Journal of Medical Sciences, 2010
- Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKDAmerican Journal of Kidney Diseases, 2008
- Temporal changes of the plasma levels of cystatin C, β‐trace protein, β2‐microglobulin, urate and creatinine during pregnancy indicate continuous alterations in the renal filtration processScandinavian Journal of Clinical and Laboratory Investigation, 2007
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005